Zura Bio Ltd reports results for the quarter ended in December - Earnings Summary

Zura Bio

28/03/2024 10:43

* Zura Bio Ltd  ZURA.OQ  reported a quarterly adjusted loss
of 19
cents​​ per share for the quarter ended in December.  The mean
expectation of five analysts for the quarter was for a loss
of 23 cents per share. Wall Street expected results to range
from -27 cents to -19 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Zura Bio Ltd's reported EPS for the quarter was a loss
of 19
cents​.
    * The company reported a quarterly loss of $6.28 million.
    * Zura Bio Ltd shares had fallen by 50.3% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Zura Bio Ltd is
$17.00 
This summary was machine generated from LSEG data March 28 at
10:43 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.23          -0.19          Beat
 Sep. 30 2023      -0.25          -0.18          Beat
 Jun. 30 2023      -0.25          -1.31          Missed